TSP Capital Management Group LLC Acquires 46,900 Shares of Novavax, Inc. $NVAX

TSP Capital Management Group LLC lifted its holdings in Novavax, Inc. (NASDAQ:NVAX) by 3.5% in the 2nd quarter, Holdings Channel.com reports. The firm owned 1,399,065 shares of the biopharmaceutical company’s stock after acquiring an additional 46,900 shares during the quarter. Novavax makes up about 2.8% of TSP Capital Management Group LLC’s holdings, making the stock its 17th largest holding. TSP Capital Management Group LLC’s holdings in Novavax were worth $8,814,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bayforest Capital Ltd bought a new position in Novavax in the first quarter worth approximately $404,000. Kingstone Capital Partners Texas LLC bought a new stake in Novavax during the 2nd quarter valued at $1,016,000. Park West Asset Management LLC bought a new stake in Novavax during the 1st quarter valued at $16,210,000. Shah Capital Management increased its holdings in shares of Novavax by 3.4% in the 2nd quarter. Shah Capital Management now owns 11,511,780 shares of the biopharmaceutical company’s stock valued at $72,524,000 after acquiring an additional 379,934 shares during the period. Finally, Entropy Technologies LP purchased a new position in shares of Novavax in the 1st quarter valued at $191,000. 53.04% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. HC Wainwright boosted their target price on shares of Novavax from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Cantor Fitzgerald assumed coverage on shares of Novavax in a research note on Friday, October 24th. They issued an “overweight” rating and a $18.00 target price for the company. Bank of America reaffirmed an “underperform” rating and set a $7.00 price target (down from $9.00) on shares of Novavax in a research report on Wednesday, August 20th. B. Riley reiterated a “buy” rating and set a $16.00 price objective (down previously from $18.00) on shares of Novavax in a report on Monday, November 10th. Finally, Wall Street Zen cut Novavax from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $11.25.

Novavax Stock Down 3.4%

NASDAQ:NVAX opened at $6.57 on Wednesday. The company has a current ratio of 2.36, a quick ratio of 2.34 and a debt-to-equity ratio of 5.93. Novavax, Inc. has a twelve month low of $5.01 and a twelve month high of $11.55. The company has a market cap of $1.07 billion, a PE ratio of 2.88, a P/E/G ratio of 0.12 and a beta of 2.68. The company’s 50 day moving average is $8.30 and its two-hundred day moving average is $7.60.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Thursday, November 6th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.08) by ($0.17). The company had revenue of $70.45 million for the quarter, compared to analysts’ expectations of $55.63 million. Novavax had a net margin of 39.20% and a negative return on equity of 142.33%. Novavax’s quarterly revenue was down 16.7% compared to the same quarter last year. During the same period last year, the firm earned ($0.76) earnings per share. Novavax has set its FY 2025 guidance at EPS. Analysts anticipate that Novavax, Inc. will post -1.46 EPS for the current year.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.